Tempus AI Gets FDA Clearance for ECG-Based Heart Valve AI Tool
Tempus AI has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new artificial intelligence product that can identify signs associated with undiagnosed moderate or severe mitral regurgitation, expanding the company’s growing presence in AI-powered cardiovascular care.
The product, called Tempus ECG-MR, analyzes standard 12-lead resting electrocardiograms (ECGs) and is designed to flag patients who may require further evaluation for mitral regurgitation, a form of heart valve disease. The clearance announced on September 28, 2026, makes ECG-MR the fourth FDA-cleared ECG-AI product in Tempus’ cardiovascular portfolio.
For investors, the announcement is important less because of an immediate revenue impact and more because it shows how Tempus is attempting to turn its AI and clinical-data infrastructure into a broader portfolio of healthcare products.
What Is Tempus ECG-MR?
Mitral regurgitation occurs when the mitral valve does not close properly, allowing blood to flow backward through the valve. In its early stages, the condition can produce few or nonspecific symptoms, meaning some patients may remain undiagnosed until the disease becomes more advanced.
Tempus ECG-MR is intended to provide an additional screening signal using an ECG that is already commonly collected in clinical settings.
The software analyzes resting, non-ambulatory 12-lead ECG recordings and detects signs associated with moderate or severe mitral regurgitation. It is intended for patients aged 65 or older who are at risk of cardiovascular disease, including people with factors such as coronary artery disease, hypertension, obesity or diabetes, as well as certain symptoms of heart disease.
Importantly, the product is not a stand-alone diagnostic tool. Its output is binary and is meant to be interpreted alongside the patient's original ECG, other diagnostic tests, symptoms and clinical history.
That distinction matters for investors because FDA clearance does not mean the software independently diagnoses heart-valve disease or replaces echocardiography and other established diagnostic procedures.
Why the FDA Clearance Matters
The bigger strategic significance is the expansion of Tempus' ECG-AI platform.
The company previously secured FDA clearance for products targeting atrial fibrillation, low left ventricular ejection fraction and pulmonary hypertension. ECG-MR now extends that portfolio into valvular heart disease.
This creates the possibility of using one existing clinical data source—the ECG—to identify signals associated with multiple cardiovascular conditions.
That is particularly relevant to Tempus' broader AI strategy. Instead of developing a standalone diagnostic workflow for every disease, the company is building algorithms that can work with clinical data already generated during routine care.
Tempus says its ECG-AI solutions are designed to work with existing ECG platforms and electronic health record systems, potentially making deployment easier than requiring hospitals to purchase an entirely new diagnostic infrastructure.
Tempus Is Building a Broader Cardiovascular AI Platform
ECG-MR arrives only about a month after Tempus received FDA clearance for ECG-PH, its AI product designed to identify signs associated with pulmonary hypertension.
The August clearance was the company's third FDA-cleared cardiovascular ECG-AI device at the time. The latest mitral-regurgitation clearance takes the number to four.
The sequence is significant because it suggests Tempus is expanding from individual AI algorithms toward a wider cardiovascular technology portfolio.
Earlier products focused on different clinical problems. ECG-AF is designed to identify signs associated with atrial fibrillation or flutter within the following 12 months in specified patients, while ECG-Low EF identifies signs associated with low left ventricular ejection fraction.
Adding pulmonary vascular and valvular disease broadens the potential clinical use cases.
The commercial opportunity, however, will depend on more than regulatory clearance. Hospitals and physicians still need to adopt the technology, integrate it into workflows and determine how it affects follow-up testing and patient management.
What It Means for Tempus AI's Business
Tempus' core business remains much larger than its cardiovascular AI products.
In the second quarter of 2026, the company reported $382.5 million in total revenue, up 22% year over year. Diagnostics revenue was $289.3 million, while Data and Applications generated $93.2 million. The company also reported $5.6 million in GAAP net income and $8.0 million in adjusted EBITDA.
Tempus ended June with $820.7 million in cash and marketable securities and raised its 2026 revenue guidance to between $1.595 billion and $1.605 billion, with adjusted EBITDA expected to be approximately $65 million.
These figures provide useful context: the ECG-MR announcement is currently better viewed as a portfolio expansion and potential future growth driver than as a separately material revenue contributor.
If Tempus can successfully commercialize several cardiovascular AI tools through existing healthcare relationships, the combined opportunity could become more meaningful over time.
Why Investors Should Watch the ECG-AI Strategy
One potential advantage of the strategy is the reuse of existing infrastructure.
An ECG is already a familiar clinical test. If AI can extract additional information from the same recording, hospitals may be able to obtain additional clinical insights without introducing a completely separate testing process.
For Tempus, this could also strengthen the value of its broader clinical-data and AI capabilities.
The company says it has connections with roughly 65% of U.S. academic medical centers and about 55% of U.S. oncologists, alongside a large multimodal data infrastructure.
However, those relationships do not automatically translate into cardiovascular revenue. Investors will need to watch actual adoption, reimbursement, customer contracts and evidence that clinicians are incorporating the algorithms into routine workflows.
Risks and Limitations
The first risk is clinical adoption. FDA clearance removes a regulatory hurdle, but hospitals still have to implement the technology and physicians have to use its results.
The second is reimbursement. Even a cleared medical AI product needs a sustainable commercial model. Coverage and payment policies can influence how quickly hospitals adopt new technologies.
There is also competition. AI-based cardiovascular diagnostics are being developed by multiple healthcare technology companies, while conventional diagnostic methods remain essential.
Finally, Tempus itself warns that its forward-looking statements are subject to risks involving competition, regulation, customer adoption, intellectual property, financing and broader economic conditions.
For investors, the key question is therefore not simply how many FDA clearances Tempus receives, but whether those clearances eventually translate into recurring revenue and stronger margins.
What to Watch Next
The next important indicators will be commercial deployment of ECG-MR, physician and hospital adoption, reimbursement developments and evidence around how the product fits into real-world clinical workflows.
Investors should also continue tracking Tempus' core oncology diagnostics and Data and Applications businesses because those segments currently account for the bulk of the company's revenue.
The company's recent cardiovascular expansion is occurring alongside other AI initiatives. In September, Tempus was selected for up to $9.5 million in ARPA-H funding to develop an autonomous clinical AI agent for heart-failure care, further highlighting the company's push into cardiovascular AI.
Conclusion
Tempus AI's FDA clearance for ECG-MR expands its ECG-based artificial intelligence portfolio into mitral regurgitation and gives the company its fourth FDA-cleared ECG-AI product. The technology is designed to flag signs of moderate or severe mitral regurgitation from standard 12-lead ECGs, helping identify patients who may need further diagnostic evaluation.
For investors, the immediate significance is strategic rather than purely financial. The development strengthens Tempus' broader effort to build a multi-condition cardiovascular AI platform. The key factor to monitor now is whether regulatory progress turns into real-world clinical adoption, reimbursement and measurable commercial growth.
Follow AIViralHub for more updates on AI, healthcare technology, stocks and global business developments.
This article is for informational and educational purposes only and should not be considered investment advice.